Fighting Post-COVID and ME/CFS - development of curative therapies.
COVID-19
ME/CFS
autoantibodies
clinical trials
endothelial dysfunction
inflammation
post-COVID
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
03
2023
accepted:
26
05
2023
medline:
3
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.
Identifiants
pubmed: 37396922
doi: 10.3389/fmed.2023.1194754
pmc: PMC10309204
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1194754Informations de copyright
Copyright © 2023 Scheibenbogen, Bellmann-Strobl, Heindrich, Wittke, Stein, Franke, Prüss, Preßler, Machule, Audebert, Finke, Zimmermann, Sawitzki, Meisel, Toelle, Krueger, Aschenbrenner, Schultze, Beyer, Ralser, Mülleder, Sander, Konietschke, Paul, Stojanov, Bruckert, Hedderich, Knolle, Riemekasten, Vehreschild, Cornely, Behrends and Burock.
Déclaration de conflit d'intérêts
The Charité Universitaetsmedizin Berlin holds a patent for the use of vericiguat in Post-COVID Syndrome. CS, JB-S, CH, KW, ES, CaF, HPru, HPre, M-LM, HA, ChF, HZ, BS, CM, MT, AK, MR, MM, LS, FKo, FP, LB, and SB are employed at Charité Universitaetsmedizin Berlin. CM was employed by Labor Berlin - Charité Vivantes GmbH. The remaining authors declare that the research was conducted in the absence of any comercial or financial relationships that could be construed as a potential conflict of interest. The Handling Editor NS declared a past collaboration with the Author CS.
Références
J Infect. 2022 Feb;84(2):158-170
pubmed: 34813820
Chest. 2022 Nov;162(5):1116-1126
pubmed: 35526605
J Investig Med. 2022 Jan;70(1):61-67
pubmed: 34611034
Intern Med. 2021 Aug 15;60(16):2577-2584
pubmed: 33896862
Int J Mol Sci. 2022 Nov 08;23(22):
pubmed: 36430175
Front Neurol. 2023 Feb 24;14:1090747
pubmed: 36908615
N Engl J Med. 2020 Oct 8;383(15):1497-1498
pubmed: 33027579
Nat Med. 2022 Jul;28(7):1461-1467
pubmed: 35614233
Front Immunol. 2020 Apr 09;11:578
pubmed: 32328064
Cell. 2022 Mar 3;185(5):881-895.e20
pubmed: 35216672
PLoS One. 2020 Oct 29;15(10):e0240403
pubmed: 33119613
Nat Rev Microbiol. 2023 Mar;21(3):133-146
pubmed: 36639608
Nat Commun. 2022 Apr 5;13(1):1812
pubmed: 35383197
J Transl Med. 2021 Feb 3;19(1):50
pubmed: 33536023
J Transl Med. 2022 Mar 22;20(1):138
pubmed: 35317812
Genome Med. 2021 Jan 13;13(1):7
pubmed: 33441124
Front Neurol. 2019 Jan 10;9:1033
pubmed: 30687207
Ann Intern Med. 2019 May 7;170(9):585-593
pubmed: 30934066
Acta Clin Belg. 2016 Dec;71(6):407-414
pubmed: 27351244
PLoS One. 2023 Feb 2;18(2):e0280942
pubmed: 36730360
Bioelectron Med. 2023 Jan 18;9(1):2
pubmed: 36650574
EClinicalMedicine. 2022 Jul;49:101495
pubmed: 35702332
Curr Opin Immunol. 2022 Aug;77:102228
pubmed: 35724449
PLoS One. 2015 Jul 01;10(7):e0129898
pubmed: 26132314
Nat Commun. 2022 Aug 30;13(1):5104
pubmed: 36042189
Drugs Today (Barc). 2021 May;57(5):321-336
pubmed: 34061127
J Neurol. 2023 Apr;270(4):2096-2105
pubmed: 36598575
Brain Behav Immun. 2021 Jul;95:245-255
pubmed: 33794313
Lancet. 2022 Aug 6;400(10350):452-461
pubmed: 35934007
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7150-E7158
pubmed: 28760971
Sci Adv. 2015 Feb;1(1):
pubmed: 26079000
Brain Behav Immun Health. 2022 Oct;24:100485
pubmed: 35814187
Ann Clin Transl Neurol. 2022 Feb;9(2):141-154
pubmed: 35060361
Biomedicines. 2021 Oct 26;9(11):
pubmed: 34829769
Multidiscip Respir Med. 2022 Dec 23;17:886
pubmed: 36636645
Front Immunol. 2022 Sep 27;13:981532
pubmed: 36238301
Psychiatry Res. 2013 May 15;207(1-2):127-33
pubmed: 23062791
Nat Med. 2022 May;28(5):911-923
pubmed: 35585196
EClinicalMedicine. 2023 Apr;58:101874
pubmed: 36873426
Medicina (Kaunas). 2021 May 19;57(5):
pubmed: 34069603
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34263741
Clin Drug Investig. 2020 May;40(5):433-447
pubmed: 32222912
Cell Syst. 2020 Jul 22;11(1):11-24.e4
pubmed: 32619549
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Nat Med. 2022 Aug;28(8):1706-1714
pubmed: 35879616
Sci Rep. 2022 Jul 12;12(1):11252
pubmed: 35821512
Nature. 2022 Aug;608(7922):258-260
pubmed: 35945375
Eur J Epidemiol. 2022 Aug;37(8):849-870
pubmed: 35904671
Bioorg Med Chem Lett. 2021 Apr 15;38:127862
pubmed: 33609659
Clin Infect Dis. 2021 Dec 6;73(11):e3740-e3746
pubmed: 33367564
Brain Behav Immun. 2023 Mar;109:139-143
pubmed: 36657623
Drugs. 2021 Sep;81(14):1605-1626
pubmed: 34609725
J Transl Med. 2021 Apr 19;19(1):159
pubmed: 33874961
Public Health Rev. 2022 Mar 15;43:1604501
pubmed: 35359614
Lancet. 2022 Jul 30;400(10349):359-368
pubmed: 35908569
Eur Respir J. 2023 Jan 12;61(1):
pubmed: 36137590
PLoS Med. 2022 Nov 10;19(11):e1004122
pubmed: 36355754